Objective: To compare the efficacy and the period of use of tocilizumab and infliximab during treatment of rheumatoid arthritis patients.
Methods: The period of use of two biologics with different mechanisms of action were compared in treatment of rheumatoid arthritis patients.
Res Ults: Both medications showed efficacy, but the period of use with no loss of efficacy was longer in patients receiving tocilizumab when compared to infliximab.
Conclusion: Tocilizumab maintains a period of use significantly longer as compared with infliximab in patients with rheumatoid arthritis treated at a single organization.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880388 | PMC |
| http://dx.doi.org/10.1590/s1679-45082013000400015 | DOI Listing |
Publication Analysis
Top Keywords
rheumatoid arthritis
12
efficacy period
8
treatment rheumatoid
8
period
5
retention rates
4
rates infliximab
4
tocilizumab
4
infliximab tocilizumab
4
tocilizumab 3-year
4
3-year period
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!